JP Morgan Week 2025 – Phil Johnson

Digital
JP Morgan Week 2025 – Phil Johnson exclusive interview

Phil Johnson started about four months ago as chief commercial officer at Evidation. He sat down on the sidelines of JP Morgan last month with pharmaphorum editor-in-chief Jonah Comstock to chat about why he joined up and his excitement about the company’s mission.

Johnson explains how Evidation creates an opt-in platform for patients to share their data for research purposes in exchange for rewards – and why the data that process creates is more valuable than the stores of data that researchers currently rely on. That includes a discussion of why data de-identification is a double-edged sword when it comes to RWD for drug developers.

The wide-ranging conversation also covers how AI is – and isn’t – changing data needs in drug discovery and why generative AI, fuelled by high-quality real-world data, is going to be bigger for disease prevention than for disease treatment.

It’s a long interview, but a good one, as Johnson brings a unique perspective to the exciting topic of real-world data, so stick around for the whole engaging conversation.